Olvera CR

Language: Spanish
References: 12
Page: 151-159
PDF size: 315.71 Kb.

ABSTRACT

Introduction: At the National Institute of Respiratory Disease, information on secondary pharmacoresistance is available since 1991. Considering the importance of this topic as indicator of the efficiency in antituberculous treatment, information was revised from 1991-1993 and from 1994-1996 and compared with that from 1997-2000. Objective: To estimate the incidence and prevalence as well as the tendency to pharmacoresistance in patients registered at the National Institute of Respiratory Disease and to determine the geographical distribution and evaluate treatment efficiency at the health units. Material and methods: Used terms are defined: pharmacoresistance, multiresistance, treatment efficiency, relapse and retreatment. Information was revised on 1,705 tuberculosis patients is registered at the Clinical research Department of the National Institute of Respiratory Disease, of which 1,459 were pulmonary and 246 extrapulmonary. Of the pulmonary patients, 275 clinical charts were registered as relapses or retreatment corresponding to categories II and IV of the World Health Organization and results on drug sensitivity to sort them by year and federative entity. Results: Prevalence of pharmacoresistance during the period 1997-2000 was 15.8% higher than during the period 1994-1996 (13.0%). Discussion: Information gathered from the treatment history of patients reveals that pharmacoresistance is originated by medical error and deficient organization in the treatment of tuberculosis. Conclusions: The solution to abate pharmacoresistance in tuberculosis is that both authorities and health staff should assume their compromise at national level, on the one hand, to strengthen the Short Course Directly Observed Therapy or with Short Course Strictly Observed Therapy, which has had good results in treatment efficiency, and on the other, to stimulate State officials to organize and equip their administrative units (sanitary jurisdiction) making them able to comply with the activities of the Tuberculosis Control Program and those of general health.

REFERENCES

1. Olvera CR, Pérez GLE. Resistencia secundaria en tuberculosis. Rev Inst Nal Enf Resp Mex 1993;6:185-190.

2. WHO. OMS Division of Communicable Diseases, Tuberculosis Unit. Guidelines for tuberculosis treatment in adults and children in National Tuberculosis Programmes. Geneve; WHO, 1991 (WHO/TUB/91.161).

3. Olvera CR, Pérez GLE, Villalba CJ. Drug resistant tuberculosis in Mexico. The experience of the National Institute of Respiratory Diseases of Mexico. Int J Tuberc Lung Dis 1997;S-52.

4. Vareldzis BP, Grosset J, De Kantor I, Crofton J, Laszlo A, Felten M, et al. Drug-resistant tuberculosis: Laboratory issues. Tuber Lung Dis 1994;75:1-7.

5. CDC: Guidelines for preventing the transmission of Mycobacterium Tuberculosis in Health-care facilities. 1994, MMWR October 43 No.RR-13.

6. WHO. Guidelines on the management of drug resistant tuberculosis. WHO/TB/96.210.

7. Olvera CR, Pérez GLE, Villalba CJ. Tuberculosis multirresistente en México 1994 – 1997. Int J Tuberc Lung Dis 1999;9:S1,119-120.

8. Álvarez-Gordillo GC, Halperin-Frisch D, Blancarte-Melendres L, Vásquez-Castellanos JL. Factores de riesgo para resistencia a drogas antifímicas en Chiapas, México. Salud Pública Mex 1995;37:408-416.

9. Sistema Nacional de Salud. Programa Nacional de Prevención y Control de la Tuberculosis. Registro y Seguimiento de Casos, 1996.

10. Secretaría de Salud. Manual de Normas y Procedimiento para la Prevención y Control de la Tuberculosis. México, 1996.

11. Rodríguez FS, Olvera CR, Quezada ZR, Carvajal GGM, Villalba CJ. Ensayo clínico de un esquema terapéutico en enfermos tuberculosos drogorresistentes. Neumol Cir Tórax 1995:LIV:

12. Olvera CR, Rodríguez FS, Pérez GLE, Villalba CJ. Experiencia en el Instituto Nacional de Enfermedades Respiratorias sobre drogorresistencia. Boletín Epidemiología, SSA. 2001;Vol.18,No.29,julio.